Life Science Leader Blogs

  1. Will Cuba Be The World’s Next Leading Biotech Hub?
    10/17/2016

    Life Science Leader magazine was recently invited to attend The Economist’s War On Cancer healthcare forum in Boston, Sept. 28, 2016. Though all of the day’s sessions were intriguing, the one that got me up out of my chair to track down a speaker before his exit occurred at 4 p.m. Entitled, “Going Global – Examples Of Cancer Advances From Around The World,” the first person to speak was Kelvin Lee, M.D., immunology chairman from the Roswell Park Cancer Institute. Dr. Lee says that his experience in working with Cuba began quite by accident in 2011.

  2. What I Found Enlightening About ISPE’s Annual Meeting
    10/10/2016

    Have you ever attended a meeting and gotten the sense of being enlightened during someone’s presentation? I recently had such an experience at the International Society for Pharmaceutical Engineering (ISPE) annual meeting and expo in Atlanta, GA. But it was neither where I expected it, nor whom I expected it from (e.g.,, keynote speakers). Don’t get me wrong, Joseph Jimenez, Dr. Stephan Grupp, M.D., Ph.D., Nicole Pierson, and Fleming Dahl all gave fine and insightful keynotes. But my experience of enlightenment at ISPE occurred on the last day of this year’s meeting, in a rather lightly (disappointingly so) attended session.

  3. Beyond IPOs: Alternative Funding Options For Biotech Startups
    10/3/2016

    “While it is great when Morgan Stanley, JP Morgan, and Goldman are fighting to take your company public, sometimes, given the investment environment, you have to play in a ‘less elegant’ part of the finance swimming pool (e.g., Form 10s and reverse mergers).” This statement by Aftab Kherani, M.D., a partner at Aisling Capital, was made in response to the question, “What are some of the more innovative ways companies are using to raise money,” in a Q&A published in Life Science Leader magazine. It seems that not every company is going to garner the glitz and glam usually associated with taking a company public via a traditional IPO (i.e., Alibaba bringing in $26 billion). That being said, it seems important for entrepreneurs to keep in mind their end goal — getting their biopharmaceutical startup actually started up. And though the pros and cons of funding opportunities like Form 10s and reverse mergers might be “old hat” for a financial expert like Kherani, we thought, given the recent slowdown in the IPO market, it might be a good opportunity to explore why Form 10s and reverse mergers merit deeper exploration.

  4. Can A Better Patient Experience Lead To A Better Patient Outcome?
    9/8/2016

    My colleague, Ed Miseta, chief editor of Clinical Leader, recently asked, “Can Better Patient Experiences Lead To Better Medicines?” via an article he developed from an interview with Thomas Goetz, cofounder of Iodine, a digital health company. According to Miseta, Goetz is attempting to turn patient experiences into better medicines and is combining data and design to help patients locate the best treatments based on preferences, demographics, and experiences. But truthfully it wasn’t Goetz’s work that intrigued me (but still worth your reading about), but rather Miseta’s question.

  5. IO: Science Still Drives The Business
    9/2/2016

    How much science does a business person need to know? In this industry, the more the better. Without at least an excellent layperson’s understanding of the company’s scientific underpinnings, a life science executive will remain vulnerable to the greatest of all hazards in managing the business — today’s news.

  6. Rare Situation Results In Free Insights From GSK’s Global Vaccine President
    8/24/2016

    When conducting interviews my natural curiosity can result in a surplus of interesting content that often doesn’t fit with the overall theme of the final published article. When situations like these happen, I often proactively create articles for an online section called — From The Cutting Room Floor. One of my favorite examples of a cutting room floor article being able to provide valuable insight came from an interview with George Golumbeski, Ph.D., SVP of business development at Celgene. During the conversation I asked how a formally trained scientist moved into the area of business development. While his response of it being “one of the best business decisions he ever made” was fascinating, it wasn’t a fit with the overall M&A theme of the July 2015 cover story — even as a sidebar.

  7. Will Cupping Be The Next Big Health Fad?
    8/11/2016

    As I sat down to write this blog, I was struck by the idea of why certain things become popular or gain legitimacy. Malcolm Gladwell describes the magic moment when an idea, trend, or social behavior crosses a threshold and begins to spread like wildfire in his book, The Tipping Point: How Little Things Can Make a Big Difference. Still, it seems rare to witness such an event actually taking place and even more difficult to predict these “moments.” For example, most of us probably never envisioned the 2014 A.L.S. ice bucket charity challenge becoming such a meteoric sensation. But while recently watching the Olympics, I think I did notice something that I anticipate will be the next big health craze — cupping.

  8. A Commentary On Biopharma’s Current Boston Fixation
    7/15/2016

    Merck recently announced its plans to lay off R&D workers at three East Coast sites; a move that will supposedly affect less than 10 percent of discovery, preclinical, and early development employees in Kenilworth and Rahway, N.J., and North Wales, PA.

  9. Living With Pricing
    7/2/2016

    Life Science Leader Launches a Search for Common Ground

  10. BIO Still Delivers
    6/22/2016

    If the BIO International Convention did nothing but assemble the 16,000 people who came to this year’s meeting in San Francisco, simply giving them a space to talk, that alone would be a great achievement.